Profile data is unavailable for this security.
About the company
GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. It manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. It offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.
- Revenue in INR (TTM)32.74bn
- Net income in INR4.20bn
- Incorporated1924
- Employees3.84k
- LocationGlaxoSmithKline Pharmaceuticals LtdDr Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224959595
- Fax+91 2 224981526
- Websitehttp://india-pharma.gsk.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suven Pharmaceuticals Ltd | 13.35bn | 3.79bn | 120.23bn | 1.19k | 31.75 | -- | 28.28 | 9.01 | 14.88 | 14.88 | 52.40 | -- | -- | -- | -- | 11,188,770.00 | -- | -- | -- | -- | 56.31 | -- | 28.39 | -- | -- | 95.61 | -- | -- | 30.75 | -- | 25.24 | -- | -- | -- |
| Glenmark Pharmaceuticals Ltd | 126.36bn | 8.81bn | 125.69bn | 15.42k | 14.27 | -- | 8.11 | 0.9948 | 31.22 | 31.22 | 447.75 | -- | -- | -- | -- | 8,196,914.00 | -- | 6.23 | -- | 8.58 | 65.37 | 60.28 | 7.54 | 8.40 | -- | 5.25 | -- | 7.66 | 12.44 | 6.02 | -2.93 | 0.5559 | 1.09 | 4.56 |
| Sanofi India Ltd | 27.70bn | 6.21bn | 129.29bn | 2.51k | 20.83 | 10.13 | 19.51 | 4.67 | 269.47 | 269.47 | 1,202.82 | 553.96 | 1.08 | 2.97 | 20.37 | -- | 24.18 | 19.39 | 34.08 | 25.34 | 57.06 | 56.38 | 22.40 | 19.61 | 1.62 | 389.71 | 0.0182 | 56.01 | -6.31 | 2.14 | -34.29 | 13.74 | -17.19 | 22.27 |
| J B Chemicals and Pharmaceuticals Ltd | 30.12bn | 4.07bn | 151.25bn | 4.34k | 37.38 | -- | 29.54 | 5.02 | 52.29 | 52.29 | 386.99 | -- | -- | -- | -- | 6,939,050.00 | -- | 14.74 | -- | 17.47 | 63.27 | 59.83 | 13.53 | 15.46 | -- | 23.30 | -- | 29.57 | 18.69 | 12.20 | -13.98 | 15.93 | 35.25 | 75.18 |
| Ajanta Pharma Ltd | 37.31bn | 6.17bn | 154.90bn | 7.23k | 25.18 | -- | 20.77 | 4.15 | 48.01 | 48.01 | 290.34 | -- | -- | -- | -- | 5,157,714.00 | -- | 17.70 | -- | 21.07 | 71.89 | 75.70 | 16.54 | 20.68 | -- | -- | -- | 15.35 | 15.62 | 10.79 | 8.99 | 7.05 | -13.03 | -6.08 |
| Piramal Enterprises Ltd | 104.23bn | 102.74bn | 157.95bn | 13.56k | 1.55 | -- | 1.49 | 1.52 | 430.44 | 430.44 | 436.59 | -- | -- | -- | -- | 7,686,321.00 | -- | 2.44 | -- | 3.40 | 62.80 | 82.35 | 98.96 | 15.05 | -- | 1.45 | -- | 30.48 | 9.24 | 10.36 | 44.34 | 8.96 | -15.09 | 10.12 |
| Laurus Labs Ltd | 60.84bn | 9.18bn | 160.01bn | 5.13k | 17.45 | -- | 13.07 | 2.63 | 17.02 | 17.02 | 112.84 | -- | -- | -- | -- | 11,858,270.00 | -- | 11.29 | -- | 19.65 | 54.59 | 47.95 | 15.14 | 13.77 | -- | 9.94 | -- | 11.74 | 2.54 | 20.64 | -15.87 | 34.18 | 25.87 | 46.14 |
| Pfizer Limited | 24.02bn | 6.20bn | 160.24bn | 2.29k | 25.85 | -- | 21.91 | 6.67 | 135.52 | 135.52 | 524.87 | -- | -- | -- | -- | 10,511,070.00 | -- | 12.76 | -- | 16.53 | 64.72 | 60.68 | 25.82 | 21.77 | -- | 46.21 | -- | 84.05 | 16.64 | 5.04 | 23.10 | 12.71 | -9.55 | 18.47 |
| IPCA Laboratories Ltd | 60.22bn | 5.25bn | 199.53bn | 15.16k | 38.01 | -- | 25.07 | 3.31 | 20.69 | 20.69 | 237.30 | -- | -- | -- | -- | 3,973,468.00 | -- | 12.86 | -- | 16.66 | 64.44 | 59.86 | 9.01 | 14.45 | -- | 18.13 | -- | 10.26 | 7.56 | 12.67 | -22.45 | 35.36 | 28.57 | 51.57 |
| Gland Pharma Ltd | 39.43bn | 9.89bn | 207.16bn | 4.64k | 20.99 | -- | 18.35 | 5.25 | 59.91 | 59.91 | 239.01 | -- | -- | -- | -- | 8,498,823.00 | -- | -- | -- | -- | 52.67 | -- | 25.07 | -- | -- | 146.39 | -- | -- | 27.08 | -- | 21.54 | -- | -- | -- |
| GlaxoSmithKline Pharmaceuticals Limited | 32.74bn | 4.20bn | 216.11bn | 3.84k | 51.51 | -- | 44.71 | 6.60 | 24.76 | 100.12 | 193.23 | -- | -- | -- | -- | 8,525,779.00 | -- | 8.78 | -- | 13.95 | 60.55 | 53.73 | 12.81 | 10.19 | -- | 519.35 | -- | 212.53 | 12.05 | 1.79 | 32.55 | 2.48 | -35.25 | 14.87 |
| Syngene International Ltd | 29.57bn | 4.33bn | 231.31bn | 5.98k | 53.11 | -- | 29.48 | 7.82 | 10.90 | 10.90 | 74.13 | -- | -- | -- | -- | 4,948,285.00 | -- | 9.20 | -- | 12.66 | 73.58 | 70.63 | 14.66 | 18.41 | -- | 7.95 | -- | -- | 19.22 | 16.74 | -2.25 | 6.62 | 9.19 | 0.00 |
| Biocon Ltd | 98.09bn | 3.88bn | 240.64bn | 3.20k | 62.29 | -- | 16.33 | 2.45 | 3.24 | 3.24 | 81.89 | -- | -- | -- | -- | 30,624,730.00 | -- | 5.67 | -- | 7.86 | 66.74 | 60.43 | 5.22 | 12.71 | -- | 3.17 | -- | 5.23 | 14.57 | 15.85 | -12.44 | 1.16 | 20.36 | 0.00 |
| Lupin Ltd | 160.95bn | -3.24bn | 296.83bn | 19.79k | -- | -- | 46.55 | 1.84 | -7.15 | -7.15 | 353.59 | -- | -- | -- | -- | 8,133,110.00 | -- | 0.0772 | -- | 0.1081 | 58.61 | 61.21 | -1.90 | 0.1267 | -- | 5.03 | -- | 2,376.12 | 8.19 | -1.28 | -225.61 | -- | -19.25 | -11.81 |
| Aurobindo Pharma Ltd | 241.92bn | 19.98bn | 298.62bn | 21.00k | 14.95 | -- | 9.48 | 1.23 | 34.09 | 34.09 | 412.78 | -- | -- | -- | -- | 11,519,900.00 | -- | 11.53 | -- | 18.30 | 55.00 | 53.95 | 8.26 | 14.54 | -- | 39.07 | -- | 6.66 | -5.32 | 9.22 | -50.36 | 2.84 | 9.81 | 29.20 |
Data as of Mar 31 2023. Currency figures normalised to GlaxoSmithKline Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
14.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2022 | 7.01m | 4.14% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 28 Feb 2023 | 2.98m | 1.76% |
| BlackRock Investment Management (UK) Ltd.as of 28 Feb 2023 | 2.97m | 1.75% |
| Newton Investment Management Ltd.as of 31 Dec 2021 | 2.60m | 1.54% |
| ICICI Prudential Asset Management Co. Ltd.as of 28 Feb 2023 | 2.53m | 1.49% |
| General Insurance Corp. of India (Invt Port)as of 30 Sep 2022 | 2.40m | 1.42% |
| The Vanguard Group, Inc.as of 03 Mar 2023 | 1.27m | 0.75% |
| Aditya Birla Sun Life Insurance Co. Ltd.as of 28 Feb 2023 | 1.19m | 0.70% |
| SBI Funds Management Pvt Ltd.as of 28 Feb 2023 | 810.04k | 0.48% |
| BlackRock Fund Advisorsas of 01 Mar 2023 | 428.76k | 0.25% |
More ▼
Data from 31 Dec 2022 - 14 Mar 2023Source: FactSet Research Systems Inc.
